Donor-Derived Anti-CD33 CAR T-Cells Show Safety in Relapsed AML Post-Transplant

Relapse following allogeneic hematopoietic cell transplantation remains the primary driver of treatment failure for patients with acute myeloid leukemia, frequently resulting in a dismal prognosis [1, 2]. While standard salvage interventions, such as donor lymphocyte infusions or the combination of venetoclax and hypomethylating agents, are routinely employed, many patients fail to achieve durable complete remissions [1, 3]. The development of chimeric antigen receptor T-cell therapies for myeloid malignancies has been historically constrained by the scarcity of truly lineage-specific antigens and the significant risk of prolonged myelosuppression (a profound decrease in bone marrow activity resulting in low blood cell counts) [4, 5]. Although targeting antigens such as CD33 and CLL-1 has demonstrated potential in early-phase trials, identifying a safe and effective therapeutic window for cellular therapy in the post-transplant setting remains a critical clinical priority [6, 7]. A recent study evaluates a donor-derived cellular approach designed to enhance post-transplant surveillance and address these persistent therapeutic gaps.